OTTAWA, Canada, June 15 /PRNewswire/ — Epocal, Inc., a
leading edge provider of point of care technology, announced today
that it has received U.S. Food and Drug Administration (FDA)
clearance to market its new lactate test on the epoc Blood Analysis
System. Lactate measurements from the epoc System are used to
evaluate acid-base status and for diagnosis and treatment of lactic
acidosis (abnormally high acidity of the blood). The addition
of lactate to the epoc BGEM Test Card, which includes in vitro
diagnostic tests for pH, pO2, pCO2, Na, K, iCa, Hct and Glu (plus
calculated values), further expands the clinical utility of the
Company’s point of care blood gas and electrolyte platform.
Lactate on the BGEM Test Card represents the second
metabolite cleared for use on the epoc System in the past 12
months. It is also the ninth measured analyte on the
single-use test card, surpassing most competitive point of care
systems which may require multiple test devices in order to match
the same menu.
“Epocal reaffirms its commitment to patient care by adding this
critical test to its cost effective, comprehensive point of care
platform,” said Imants Lauks, Epocal
Inventor and CEO. “The epoc technology continues to excite
healthcare with its ability to improve delivery of patient care,
reduce operating expenses and increase efficiency throughout the
entire healthcare enterprise.”
About Epocal, Inc.
Epocal, Inc., headquartered in Ottawa,
ON, Canada with U.S. Sales
and Marketing operations in Horsham,
PA, develops, manufactures and markets the epoc Blood
Analysis System. epoc (enterprise point of care) is
healthcare’s first cost effec
‘/>”/>
SOURCE
